Module

Considering Drug-Drug Interactions When Selecting a First-line Antiretroviral Therapy for a Patient With a Complex Medical History

Source: The Evolving Management of Drug-Drug Interactions in HIV Infection

Considering Drug-Drug Interactions When Selecting a First-line Antiretroviral Therapy for a Patient With a Complex Medical History

Faculty:

Charles W. Flexner, MD
Paul Pham, PharmD, BCPS

CREDIT INFORMATION

Release Date: May 15, 2009

Expiration Date: May 14, 2010

Physicians: maximum of 0.5 AMA PRA Category 1 Credits™

Status: The activity is not currently available for credit.

Learning Objectives

Upon completion of this activity, participants should be able to:

Describe necessary dose adjustments when combining efavirenz and atazanavir/ritonavir
Discuss the results of the ACTG 5142 study in regards to the use of NRTI-sparing regimen, lopinavir/ritonavir and efavirenz
Summarize the pharmacokinetic differences of using once-daily vs twice-daily darunavir/ritonavir when combined with efavirenz

Abstract

Click here to view abstract

Disclaimer: The materials published on the Clinical Care Options Sites reflect the views of the reviewers or authors of the CCO material, not those of Clinical Care Options, LLC, the CME provider, or the companies providing educational grants. The materials may discuss uses and dosages for therapeutic products that have not been approved by the United States Food and Drug Administration. A qualified healthcare professional should be consulted before using any therapeutic product discussed. Readers should verify all information and data before treating patients or using any therapies described in these materials.